#########
Volume 12, Number 28
Monday, July 9, 2012
#########


JULY IS EYE INJURY PREVENTION MONTH




In this issue: (click heading to view article)
#########
######### Link Between IOP and Optic Nerve Sheath Diameter in NTG
#########
######### Expression of Regulatory Proteins on Leukocytes in Neovascular AMD
#########
######### Understanding the Hyporeflective Wedge-Shaped Band in GA Secondary to AMD
#########
######### Relationship Between Time Spent Outdoors and Myopia
#########
######### Briefly

 

 





Link Between IOP and Optic Nerve Sheath Diameter in NTG

The authors of this study aimed to: identify the differences in optic nerve sheath diameter (ONSD) as an indirect measure of intracranial pressure (ICP) in glaucoma patients and a healthy population; and identify variables that may correlate with ONSD in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG) patients. They found that indirect measurements of ICP by ultrasound assessment of the ONSD may provide further insights into the retrolaminar pressure component in glaucoma.

Patients with NTG (n=46) and POAG (n=61), and healthy controls (n=42) underwent B-scan ultrasound measurement of ONSD by an observer masked to the patient diagnosis. Intraocular pressure (IOP) was measured in all groups, with additional central corneal thickness (CCT) and visual field defect measurements in glaucomatous patients. Only one eye per patient was selected and Kruskal-Wallis or Mann-Whitney was used to compare the different variables between the diagnostic groups. Additionally, Spearman correlations were used to explore relationships among these variables.

According to the study authors, ONSD was not significantly different between healthy, NTG and POAG patients (6.09 ± 0.78, 6.03 ± 0.69, and 5.71 ± 0.83 respectively; p=0.08). Visual field damage and CCT were not correlated with ONSD in either of the glaucoma groups (POAG, p=0.31 and 0.44; NTG, p=0.48 and 0.90 respectively). However, ONSD did correlate with IOP in NTG patients (r=0.53, p<0.001), while it did not in POAG patients and health controls (p=0.86, p=0.46 respectively). The authors noted that a patient’s age did not relate to ONSD in any of the groups (p>0.25 in all groups).

The correlation of ONSD with IOP solely in NTG patients suggests that the translaminar pressure gradient may be of particular importance in this type of glaucoma.

SOURCE: Pinto LA, Vandewalle E, Pronk A, Stalmans I. Intraocular pressure correlates with optic nerve sheath diameter with norm al tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2012;250(7):1075–1080.




http://ecatalog.alcon.com/PI/Nevanac_us_en.pdf







Expression of Regulatory Proteins on Leukocytes in Neovascular AMD

Danish investigators investigated the expression of the complement regulatory proteins CD46, CD55, and CD59 on peripheral leukocytes in neovascular age-related macular degeneration (AMD) in this prospective, case-control study.

They included 35 unrelated patients with neovascular AMD and 30 control individuals. All participants were subjected to a structured interview and the investigators performed detailed imaging (autofluorescence, digital funduscopy, spectral-domain optical coherence tomography, and fluorescein and indocyanine green angiography in patients suspected of having neovascular AMD). They obtained and stained fresh ethylenediaminetetraacetic acid blood with monoclonal antibodies. Using flow cytometry, they determined the percentage of CD14+ monocytes, CD45+ lymphocytes, and CD45+ granulocytes positive for CD46, CD55, and CD59 in patients with neovascular AMD and compared this with that of controls.

They found that the expression of CD46 and CD59 was significantly lower on CD14+ monocytes in patients with neovascular AMD compared with controls (p=.0070). The investigators also observed a significantly lower expression of CD46 on lymphocytes in patients with fibrosis compared with patients without fibrosis (p=.010).

This study suggests that neovascular AMD is associated with an inadequate regulation of the complement system, supporting current evidence on the role of complement dysregulation in the pathogenesis of AMD.

SOURCE: Singh A, Faber C, Falk M, et al. Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration. Am J Ophthalmol. 2012;154(1):193–199.



http://www.revophth.com/saos2012






Understanding the Hyporeflective Wedge-Shaped Band in GA Secondary to AMD

To describe and interpret the frequently observed spectral-domain optical coherence tomography (SD-OCT) finding of a marked hyporeflective wedge-shaped structure at the boundaries of the areas of atrophy, researchers in Spain conducted the following prospective, longitudinal follow-up study.

They examined consecutive patients (n=71) 50 years of age and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) between January 2010 and June 2011. The researchers evaluated patients with the use of imaging techniques that included 35° fundus photography, infrared, fundus autofluorescence (FAF), and SD-OCT. They visualized the fundus simultaneously with FAF and OCT. They followed two acquisition protocols: a macular cube for coverage (19 horizontal B-scans centered on the fovea) and high-resolution horizontal B-scan for qualitative foveal detail. Estimation of the prevalence of a hyporeflective wedge-shaped band among patients with GA was the main outcome measure.

The study researchers observed a marked hyporeflective wedge-shaped structure, with its base on Bruch's membrane and its apex pointing toward the inner limit of the outer plexiform layer (OPL) adjacent to the margin between the atrophied area and the preserved retina in 72.9% of eyes (70/96; 95% confidence interval, 63.9–82.0). They noted that this hyporeflective band appeared to be within the OPL. Using eccentric SD-OCT acquisition, the boundaries between the outer nuclear layer (ONL) and Henle's fiber layer (HFL) were well defined, showing that the ONL ends before the margin of atrophy of the retinal pigment epithelium (RPE). A narrow hyperreflective band separated the margin of the ONL and RPE from the hyporeflective band, already within the atrophic area.

In conclusion, a hyporeflective wedge-shaped structure appears frequently within the boundaries of the OPL in patients with GA secondary to AMD, corresponding to an increase in the width of the HFL, presumably because of axonal swelling or interaxonal edema. This finding may improve the interpretation of SD-OCT images of the outer layers, may help in understanding better the interactions of between photoreceptor cells and the RPE, and may help in the development of monitoring techniques and therapies for GA secondary to AMD.

SOURCE: Monés J, Biarnés M, Trindade F. Hyporeflective wedge-shaped band in geographic atrophy secondary to age-related macular degeneration: an underreported finding. Ophthalmology. 2012;119(7):1412–1419.

 



http://www.revophth.com/avtt2012






Relationship Between Time Spent Outdoors and Myopia

The following study sought to determine whether conjunctival ultraviolet autofluorescence (UVAF), a biomarker of outdoor light exposure, is associated with myopia.

Individuals aged ≥15 years were recruited for this cross-sectional study and participants completed a sun-exposure questionnaire and underwent noncycloplegic autorefraction. Conjunctival UVAF used a specially adapted electronic flash system fitted with UV-transmission filters (transmittance range 300–400 nm, peak 365 nm) as the excitation source. Temporal and nasal conjunctival UVAF was measured in both eyes using computerized photographic analysis with the sum referred to as “total UVAF.”

In 636 participants, prevalence of myopia decreased with an increasing quartile of total UVAF (Ptrend=0.002). Median total UVAF was lower in subjects with myopia (spherical equivalent [SE]≤–1 D) than participants without myopia: 16.6 mm² versus 28.6 mm², p=0.001. In the multivariable model that adjusted for age, sex, smoking, cataract, height, and weight, UVAF was independently associated with myopia (SE≤–1.0D): odds ratio (OR) for total UVAF (per 10 mm²) was 0.81, 95% confidence interval (CI) 0.69 to 0.94, p=0.007. It was noted that UVAF was also significantly associated with myopia when analysis was restricted to subjects <50 years, and in moderate-severe myopia (SE≤–3.0D). Prevalence of myopia decreased with increasing time outdoors (Ptrend=0.03), but time outdoors was not associated with myopia on multivariable analysis.

A protective association between increasing UVAF and myopia was identified and the protective association of higher UVAF against myopia was stronger than that of increased levels of time spent outdoors as measured by this study's questionnaire. Future studies should investigate the association between UVAF and incident myopia, and its relationship to myopic progression.

SOURCE: Sherwin JC, Hewitt AW, Coroneo MT, et al. The association between time spent outdoors and myopia using a novel biomarker of outdoor light exposure. Invest Ophthalmol Vis Sci. 2012;53(8):4363–4370.




http://www.revophth.com/ResFellowEdu2012







  • FDA APPROVAL HEALON ENDOCOAT PROTECTIVE GEL FOR CATARACT SURGERY. Abbott has expanded its Healon family of ophthalmic viscosurgical devices (OVDs) with the FDA approval of Healon EndoCoat OVD, a device intended for use as a surgical aid in cataract extraction and intraocular lens (IOL) implantation. The clear, viscous, protective gel formula is injected into a patient’s eye to protect and coat the eye during surgery, reducing trauma to the inside layer of the cornea and other surrounding tissues, says Abbott. The surgical delivery system for Healon Endocoat OVD includes a number of features for increased patient safety and ease of handling for the physician, including a smaller delivery device and improved ergonomics for a smooth and consistent delivery of the formula into the eye. Read more here.
  • THROMBOGENICS' BLA FOR OCRIPLASMIN INTRAVITREAL INJECTION GRANTED PRIORITY REVIEW BY FDA. In a recent press release, ThromboGenics NV announced that the FDA has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review. The proposed indication of ocriplasmin intravitreal injection is for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole. Given its decision to grant Priority Review, the FDA has already scheduled an Advisory Committee meeting on July 26, 2012 to discuss the ocriplasmin BLA and has assigned the ocriplasmin BLA a Prescription Drug User Fee Act goal date of October 17, 2012.

 







Review of Ophthalmology® Online is published by the Professional Publications Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.

To subscribe to other JMI newsletters or to manage your subscription, click here.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add reviewophth@jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Review of Ophthalmology Online.

Advertising: For information on advertising in this e-mail newsletter or other creative advertising opportunities with Review of Ophthalmology, please contact publisher Rick Bay, or sales managers James Henne or Michele Barrett.

News: To submit news or contact the editor, send an e-mail, or FAX your news to 610.492.1049